ftInvstr
CAPLIPOINT · Healthcare ₹2794.0 -1.41% Mkt Cap ₹21142 Cr

CAPLIPOINT

Healthcare Drug Manufacturers - Specialty & Generic
₹2794.0
-1.41% today · 30d +8.09%
as of 2026-09-04
Price · Daily Candles
“Caplin Point Labs: Strong Q4 Profit Growth Fuels Rally, but Valuation Concerns Emerge”
Caplin Point Laboratories recorded a robust Q4 2026 with net profit growing 19.0% YoY to ₹173 Cr and revenue up 19.45% YoY to ₹600 Cr. However, its current price of ₹2082.0 leaves it overvalued by 33.4% based on intrinsic value analysis, and its 1-year return is down 3.66%.
BULL CASE
+Q4 2026 saw strong profit growth, with net profit increasing by 19.0% YoY to ₹173 Cr.
+Quarterly revenue surged by 19.45% YoY, reaching ₹600 Cr in Q4 2026.
+Annual net profit grew by 20.08% YoY to ₹650 Cr for the year ending March 2026.
+The company maintains a high profitability score of 92 and a low risk score of 70 based on business analytics.
BEAR CASE
The stock is currently trading at ₹2082.0, determined to be overvalued by 33.4% according to intrinsic value calculations.
FII shareholding decreased by 0.44% QoQ to 6.15% in Q4 2026.
The stock has delivered a negative 1-year return of -3.66%.
Its RSI(14) at 74.05 indicates a strong bearish signal.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-03-31
REVENUE
₹600 Cr
+19.45% YoY
NET PROFIT
₹173 Cr
+19.0% YoY
OPM
37.01%
+0.32pp YoY
EPS
₹22.38
PE 24.1
Intrinsic value · DCF: N/A — ML model predicts severe Δ FCF compression (h1=-41.3%, h2=-34.0%, h3=-33.1% of mktcap), driving projected FCF negative by year 3 despite healthy current FCF. Treating as forecast outlier rather than reporting a misleading ₹0 valuation. Use the Strategy Fit and ML sections instead.
◇ Sector Position
Caplin Point Laboratories, with a TTM PE of 24.1 and ROCE of 25.0%, appears more attractively valued than industry giants like SUNPHARMA (PE 40.41, ROCE 22.46%) and DIVISLAB (PE 69.85, ROCE 21.47%), while matching CIPLA's ROCE of 25.0%.
PEERPEROCE %
CAPLIPOINT24.125.0
SUNPHARMA40.4122.46
DIVISLAB69.8521.47
CIPLA29.4425.09
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
76
SCORE / 100
Overall
6-axis composite of the sections below.
Performance STRONG 90
Valuation REASONABLE 60
Growth STRONG 73
Profitability HIGH 92
Technicals STRONG 73
Risk LOW 70
Key Stats
TTM PE
24.1
P/B
4.5
52W HIGH
₹2877.3
OFF HIGH
-2.9%
DIV YIELD
0.39%
MKT CAP
₹21142 Cr
◉ Active Signals
MACDBullish31.3247
RSI(14)Bullish64.53
Near 52W HighBullish-2.9
Street Consensus
2 analysts
₹2505.0
mean target
Low ₹2320.0Now ₹2794.0High ₹2690.0
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold CAPLIPOINT and at what entry.

Sign up freeSign in